Drug intelligence / Profile preview

PF-00610355

Development stage
Phase 2
Lead developer
Pfizer
Modality
Small Molecules
Administration
Inhalation
01

Overview

PF-00610355 (also known as PF-610355) is an investigational, inhalable ultra-long acting β2-adrenoreceptor agonist (ultra-LABA) developed by Pfizer for the once-daily treatment of asthma and chronic obstructive pulmonary disease (COPD). It acts primarily in the lungs to induce bronchodilation by stimulating Beta2-adrenoreceptor, leading to relaxation of airway smooth muscle. The drug features a sulfonamide agonist headgroup that confers high intrinsic crystallinity and may support a zwitterionic form in the solid state. Pharmacokinetic optimization aimed to minimize systemic exposure after inhalation, reducing systemically mediated adverse events. Clinical studies reached up to phase II for COPD and asthma but development was discontinued around 2011 for strategic and regulatory reasons.

Other names
862541-45-5ZH5SMU97AJZH-5SMU97AJZH 5SMU97AJ
02

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on PF-00610355.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-00610355.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call